Lineage Cell Therapeutics, Inc. Research and Development Expense
Lineage Cell Therapeutics, Inc. (LCTX) reported Research and Development Expense of $4.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $4.77M, a 53.70% increase year-over-year.
- Lineage Cell Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $4.23M, a 35.97% increase year-over-year.
- Lineage Cell Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $8.24M, a 140.67% increase year-over-year.
- Lineage Cell Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $3.27M, a 3.15% increase year-over-year.
- Lineage Cell Therapeutics, Inc. research and development expense for fiscal 2025 was $17.73M, a 42.15% increase from fiscal 2024.
- Lineage Cell Therapeutics, Inc. research and development expense for fiscal 2024 was $12.47M, a 20.59% decline from fiscal 2023.
- Lineage Cell Therapeutics, Inc. research and development expense for fiscal 2023 was $15.71M, a 12.28% increase from fiscal 2022.
- Lineage Cell Therapeutics, Inc. research and development expense for fiscal 2022 was $13.99M, a 58.76% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.77M 10-Q · filed 2026-08-06 | $9.01M 10-Q · filed 2026-08-06 | $17.25M derived: sum of 3 quarters · filed 2026-08-06 | $20.52M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $4.23M 10-Q · filed 2026-05-12 | $12.47M derived: sum of 2 quarters · filed 2026-05-12 | $15.74M derived: sum of 3 quarters · filed 2026-05-12 | $18.85M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $8.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $11.51M derived: sum of 2 quarters · filed 2026-03-05 | $14.62M derived: sum of 3 quarters · filed 2026-08-06 | $17.73M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $3.27M 10-Q · filed 2025-11-06 | $6.38M derived: sum of 2 quarters · filed 2026-08-06 | $9.49M 10-Q · filed 2025-11-06 | $12.91M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $3.11M 10-Q · filed 2026-08-06 | $6.22M 10-Q · filed 2026-08-06 | $9.64M derived: sum of 3 quarters · filed 2026-08-06 | $12.81M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $3.11M 10-Q · filed 2026-05-12 | $6.54M derived: sum of 2 quarters · filed 2026-05-12 | $9.71M derived: sum of 3 quarters · filed 2026-05-12 | $12.58M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $6.59M derived: sum of 2 quarters · filed 2026-03-05 | $9.46M derived: sum of 3 quarters · filed 2026-03-05 | $12.47M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $3.17M 10-Q · filed 2025-11-06 | $6.04M derived: sum of 2 quarters · filed 2025-11-06 | $9.05M 10-Q · filed 2025-11-06 | $12.96M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | $2.87M 10-Q · filed 2025-08-12 | $5.88M 10-Q · filed 2025-08-12 | $9.78M derived: sum of 3 quarters · filed 2025-08-12 | $13.53M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $3.01M 10-Q · filed 2025-05-13 | $6.92M derived: sum of 2 quarters · filed 2025-05-13 | $10.66M derived: sum of 3 quarters · filed 2025-05-13 | $14.53M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $7.65M derived: sum of 2 quarters · filed 2025-03-10 | $11.52M derived: sum of 3 quarters · filed 2025-03-10 | $15.71M 10-K · filed 2025-03-10 | ||||
| 2023-09-30 | $3.74M 10-Q · filed 2024-11-14 | $7.61M derived: sum of 2 quarters · filed 2024-11-14 | $11.80M 10-Q · filed 2024-11-14 | $15.90M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $3.87M 10-Q · filed 2024-08-08 | $8.06M 10-Q · filed 2024-08-08 | $12.16M derived: sum of 3 quarters · filed 2024-08-08 | $15.75M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $4.18M 10-Q · filed 2024-05-09 | $8.29M derived: sum of 2 quarters · filed 2024-05-09 | $11.88M derived: sum of 3 quarters · filed 2024-05-09 | $15.18M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $7.70M derived: sum of 2 quarters · filed 2024-03-07 | $11.00M derived: sum of 3 quarters · filed 2024-03-07 | $13.99M 10-K · filed 2024-03-07 | ||||
| 2022-09-30 | $3.59M 10-Q · filed 2023-11-09 | $6.89M derived: sum of 2 quarters · filed 2023-11-09 | $9.88M 10-Q · filed 2023-11-09 | $34.66M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | $3.30M 10-Q · filed 2023-08-10 | $6.29M 10-Q · filed 2023-08-10 | $31.07M derived: sum of 3 quarters · filed 2023-08-10 | $33.88M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $2.99M 10-Q · filed 2023-05-11 | $27.77M derived: sum of 2 quarters · filed 2023-05-11 | $30.58M derived: sum of 3 quarters · filed 2023-05-11 | $33.51M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $24.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $27.59M derived: sum of 2 quarters · filed 2023-03-09 | $30.52M derived: sum of 3 quarters · filed 2023-03-09 | $33.91M 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | $2.81M 10-Q · filed 2022-11-10 | $5.74M derived: sum of 2 quarters · filed 2022-11-10 | $9.14M 10-Q · filed 2022-11-10 | $11.74M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $2.93M 10-Q · filed 2022-08-11 | $6.33M 10-Q · filed 2022-08-11 | $8.93M derived: sum of 3 quarters · filed 2022-08-11 | $12.50M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $3.39M 10-Q · filed 2022-05-12 | $6.00M derived: sum of 2 quarters · filed 2022-05-12 | $9.57M derived: sum of 3 quarters · filed 2022-05-12 | $12.37M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $6.17M derived: sum of 2 quarters · filed 2022-03-10 | $8.98M derived: sum of 3 quarters · filed 2022-03-10 | $12.32M 10-K · filed 2022-03-10 | ||||
| 2020-09-30 | $3.57M 10-Q · filed 2021-11-10 | $6.37M derived: sum of 2 quarters · filed 2021-11-10 | $9.71M 10-Q · filed 2021-11-10 | $13.20M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $2.81M 10-Q · filed 2021-08-12 | $6.14M 10-Q · filed 2021-08-12 | $9.63M derived: sum of 3 quarters · filed 2021-08-12 | $13.90M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $3.34M 10-Q · filed 2021-05-13 | $6.83M derived: sum of 2 quarters · filed 2021-05-13 | $11.09M derived: sum of 3 quarters · filed 2021-05-13 | $16.33M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $3.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $7.75M derived: sum of 2 quarters · filed 2021-03-11 | $12.99M derived: sum of 3 quarters · filed 2021-03-11 | $17.95M 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | $4.27M 10-Q · filed 2020-11-04 | $9.50M derived: sum of 2 quarters · filed 2020-11-04 | $14.46M 10-Q · filed 2020-11-04 | $18.24M derived: sum of 4 quarters · filed 2020-11-04 | ||||
| 2019-06-30 | $5.24M 10-Q · filed 2020-08-06 | $10.20M 10-Q · filed 2020-08-06 | $13.98M derived: sum of 3 quarters · filed 2020-08-06 | $18.86M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $4.96M 10-Q · filed 2020-05-07 | $8.74M derived: sum of 2 quarters · filed 2020-05-07 | $13.62M derived: sum of 3 quarters · filed 2020-05-07 | $19.98M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $3.78M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $8.66M derived: sum of 2 quarters · filed 2020-03-12 | $15.02M derived: sum of 3 quarters · filed 2020-03-12 | $20.95M 10-K · filed 2020-03-12 | ||||
| 2018-09-30 | $4.88M 10-Q · filed 2019-11-12 | $11.24M derived: sum of 2 quarters · filed 2019-11-12 | $17.18M 10-Q · filed 2019-11-12 | $21.87M derived: sum of 4 quarters · filed 2019-11-12 | ||||
| 2018-06-30 | $6.36M 10-Q · filed 2019-08-08 | $12.29M 10-Q · filed 2019-08-08 | $16.99M derived: sum of 3 quarters · filed 2019-08-08 | $23.55M derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | $5.93M 10-Q · filed 2019-05-09 | $10.63M derived: sum of 2 quarters · filed 2019-05-09 | $17.19M derived: sum of 3 quarters · filed 2019-05-09 | $23.46M derived: sum of 4 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | $4.70M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $11.26M derived: sum of 2 quarters · filed 2019-03-14 | $17.53M derived: sum of 3 quarters · filed 2019-03-14 | $24.02M 10-K · filed 2019-03-14 | ||||
| 2017-09-30 | $6.56M 10-Q · filed 2018-11-08 | $12.83M derived: sum of 2 quarters · filed 2018-11-08 | $19.33M 10-Q · filed 2018-11-08 | $26.34M derived: sum of 4 quarters · filed 2018-11-08 | ||||
| 2017-06-30 | $6.27M 10-Q · filed 2018-08-02 | $12.77M 10-Q · filed 2018-08-02 | $19.78M derived: sum of 3 quarters · filed 2018-08-02 | $26.20M derived: sum of 4 quarters · filed 2018-08-02 | ||||
| 2017-03-31 | $6.49M 10-Q · filed 2018-05-10 | $13.51M derived: sum of 2 quarters · filed 2018-05-10 | $19.93M derived: sum of 3 quarters · filed 2018-05-10 | $28.87M derived: sum of 4 quarters · filed 2018-05-10 | ||||
| 2016-12-31 | $7.01M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $13.44M derived: sum of 2 quarters · filed 2018-03-15 | $22.37M derived: sum of 3 quarters · filed 2018-03-15 | $36.11M 10-K · filed 2018-03-15 | ||||
| 2016-09-30 | $6.42M 10-Q · filed 2017-11-09 | $15.36M derived: sum of 2 quarters · filed 2017-11-09 | $29.09M 10-Q · filed 2017-11-09 | $41.88M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-06-30 | $8.94M 10-Q · filed 2017-08-09 | $22.67M 10-Q · filed 2017-08-09 | $35.46M derived: sum of 3 quarters · filed 2018-03-15 | $46.89M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-03-31 | $13.73M 10-Q · filed 2017-05-10 | $26.52M derived: sum of 2 quarters · filed 2018-03-15 | $37.95M derived: sum of 3 quarters · filed 2018-03-15 | $47.01M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2015-12-31 | $12.79M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $24.22M derived: sum of 2 quarters · filed 2018-03-15 | $33.28M derived: sum of 3 quarters · filed 2018-03-15 | $42.60M 10-K · filed 2018-03-15 | ||||
| 2015-09-30 | $11.43M 10-Q · filed 2016-11-04 | $20.49M derived: sum of 2 quarters · filed 2016-11-04 | $29.82M 10-Q · filed 2016-11-04 | $41.08M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | $9.06M 10-Q · filed 2016-08-09 | $18.38M 10-Q · filed 2016-08-09 | $29.65M derived: sum of 3 quarters · filed 2017-03-16 | $38.48M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | $9.32M 10-Q · filed 2016-05-10 | $9.32M 10-Q · filed 2015-05-08 | $20.59M derived: sum of 2 quarters · filed 2017-03-16 | $29.42M derived: sum of 3 quarters · filed 2017-03-16 | $38.51M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $11.27M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $20.10M derived: sum of 2 quarters · filed 2017-03-16 | $29.18M derived: sum of 3 quarters · filed 2017-03-16 | $37.53M 10-K · filed 2017-03-16 | $37.53M 10-K · filed 2015-03-11 | |||
| 2014-09-30 | $8.84M 10-Q · filed 2015-11-09 | $8.84M 10-Q · filed 2014-11-07 | $17.92M derived: sum of 2 quarters · filed 2015-11-09 | $26.27M 10-Q · filed 2015-11-09 | $26.27M 10-Q · filed 2014-11-07 | $35.54M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-06-30 | $9.08M 10-Q · filed 2015-08-10 | $9.08M 10-Q · filed 2014-08-11 | $17.47M 10-Q · filed 2015-08-10 | $17.47M 10-Q · filed 2014-08-11 | $26.71M derived: sum of 3 quarters · filed 2016-03-15 | $33.15M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-03-31 | $8.41M 10-Q · filed 2015-05-08 | $17.62M derived: sum of 2 quarters · filed 2016-03-15 | $24.07M derived: sum of 3 quarters · filed 2016-03-15 | $29.60M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2013-12-31 | $9.22M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $15.66M derived: sum of 2 quarters · filed 2016-03-15 | $21.19M derived: sum of 3 quarters · filed 2016-03-15 | $26.61M 10-K · filed 2016-03-15 | $26.61M 10-K · filed 2014-03-17 | |||
| 2013-09-30 | $6.44M 10-Q · filed 2014-11-07 | $11.97M derived: sum of 2 quarters · filed 2014-11-07 | $17.39M 10-Q · filed 2014-11-07 | $22.16M derived: sum of 4 quarters · filed 2015-03-11 | ||||
| 2013-06-30 | $5.53M 10-Q · filed 2014-08-11 | $10.98M 10-Q · filed 2014-08-11 | $15.72M derived: sum of 3 quarters · filed 2015-03-11 | $20.26M derived: sum of 4 quarters · filed 2015-03-11 | ||||
| 2013-03-31 | $5.40M 10-Q · filed 2014-05-12 | $10.19M derived: sum of 2 quarters · filed 2015-03-11 | $14.73M derived: sum of 3 quarters · filed 2015-03-11 | $19.35M derived: sum of 4 quarters · filed 2015-03-11 | ||||
| 2012-12-31 | $4.79M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | $9.34M derived: sum of 2 quarters · filed 2015-03-11 | $13.95M derived: sum of 3 quarters · filed 2015-03-11 | $18.12M 10-K · filed 2015-03-11 | ||||
| 2012-09-30 | $4.55M 10-Q · filed 2013-11-12 | $9.16M derived: sum of 2 quarters · filed 2013-11-12 | $13.32M 10-Q · filed 2013-11-12 | $17.28M derived: sum of 4 quarters · filed 2014-03-17 | ||||
| 2012-06-30 | $4.62M 10-Q · filed 2013-08-09 | $8.77M 10-Q · filed 2013-08-09 | $12.74M derived: sum of 3 quarters · filed 2014-03-17 | $16.23M derived: sum of 4 quarters · filed 2014-03-17 | ||||
| 2012-03-31 | $4.18M 10-Q · filed 2013-05-10 | $8.12M derived: sum of 2 quarters · filed 2014-03-17 | $11.61M derived: sum of 3 quarters · filed 2014-03-17 | $14.94M derived: sum of 4 quarters · filed 2014-03-17 | ||||
| 2011-12-31 | $3.94M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $7.43M derived: sum of 2 quarters · filed 2014-03-17 | $10.77M derived: sum of 3 quarters · filed 2014-03-17 | $13.70M 10-K · filed 2014-03-17 | -$13.70M 10-K · filed 2012-03-14 | |||
| 2011-09-30 | $3.49M 10-Q · filed 2012-11-09 | -$3.45M 10-Q · filed 2011-11-08 | $6.82M derived: sum of 2 quarters · filed 2012-11-09 | $9.76M 10-Q · filed 2012-11-09 | -$9.57M 10-Q · filed 2011-11-08 | $22.36M derived: sum of 4 quarters · filed 2013-03-18 | ||
| 2011-06-30 | $3.33M 10-Q · filed 2012-08-09 | -$3.29M 10-Q · filed 2011-08-09 | $6.28M 10-Q · filed 2012-08-09 | -$6.14M 10-Q · filed 2011-08-09 | $18.87M derived: sum of 3 quarters · filed 2013-03-18 | $17.06M derived: sum of 4 quarters · filed 2013-03-18 | ||
| 2011-03-31 | $2.95M 10-Q · filed 2012-05-10 | $15.54M derived: sum of 2 quarters · filed 2013-03-18 | $13.73M derived: sum of 3 quarters · filed 2013-03-18 | $12.30M derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2010-12-31 | $12.59M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $10.78M derived: sum of 2 quarters · filed 2013-03-18 | $9.35M derived: sum of 3 quarters · filed 2013-03-18 | $8.19M 10-K · filed 2013-03-18 | -$8.19M 10-K · filed 2012-03-14 | |||
| 2010-09-30 | -$1.81M 10-Q · filed 2011-11-08 | -$3.24M derived: sum of 2 quarters · filed 2011-11-08 | -$4.40M 10-Q · filed 2011-11-08 | |||||
| 2010-06-30 | -$1.43M 10-Q · filed 2011-08-09 | -$2.59M 10-Q · filed 2011-08-09 | ||||||
| 2009-12-31 | -$3.18M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |